José Sandoval

MD (Oncologist) & Researcher @hug_ge (Geneva,CH) •PhD (@Cambridge_Uni) •MPH @LSHTM

[José Sandoval @JLSandoval]

We were awarded the Ferenc Bojan Young Investigator Award at the @EPHconference. Happy that our work got recognised and the Bus Santé is continuing to produce relevant public health research.
@iguessous @Hopitaux_unige @unige_en @UNIGEnews

[José Sandoval @JLSandoval]

@PTarantinoMD The whole system is broken. Everything is a "scientific paper". You just need to pay and it gets published somewhere.
Not sure the quality and impact of most is far from that of AI generated random stuff.
Rewarding quantity over quality causes this...

https://t.co/zPgokVgRYz

[Yakup Ergün @dr_yakupergun]

This was the journal I was referring to. I had only shared the number of articles published over a two-day period, but the more comprehensive data here is even more striking: approximately 115,000 articles published between 2022 and 2025.
At this point, I’m running out of words.
On my end, I’ve started declining reviewer invitations—there’s not much else I can realistically do. And it’s important to remember that this is just one example.

https://t.co/zv79DSQFA8

[José Sandoval @JLSandoval]

Ocafu's Tortilla, as suggested by @JavierCortesMD. Thanks for the great gourmet suggestion and mentorship over these last 3 days.

[José Sandoval @JLSandoval]

@PTarantinoMD Also new biomarkers/test are quickly patented and developed for profit, making the use of public money to pay these trials more questionable. IMO it requires a mix of gvt/insurance companies funding and a commitment to fair pricing if test/biomarker is clinically useful.

[José Sandoval @JLSandoval]

@PTarantinoMD Agree. The problem is that the cost of clinical utility trials is enormous and and even more for NI trials. There's no interest (understandably so) from pharma to invest in this topic as it would reduce their market.

[Timothée Olivier, MD @Timothee_MD]

#ESMO25
So nice to see my friend and colleague @JLSandoval co-chairing with Carolien Schröder a session focusing on tailoring breast cancer care for special populations.👍👏 @DOncologie @hug_ge

[José Sandoval @JLSandoval]

@ajumathew_ @Cambridge_Uni @CaiusCollege @ClareCollege , not very far ;)

[Timothée Olivier, MD @Timothee_MD]

Congratulations @JLSandoval et al. for this study exploring biomarkers in ovarian cancer!
Very nice collaborative effort, well done 👍 👏#ASCO25
@hug_ge @institut_curie !

[José Sandoval @JLSandoval]

Interesting data from PADA-1 trial at #esmobreast25 by FC Bidard @institut_curie

Rate of ESR1m detection changes over time suggesting selection of a subclone rather than ESR1m emergence, factors associated with ESR1m detection were identified. Same for ESR1m detection w/o PD.

[LARVOL @Larvol]

Which companies are driving the future of #BreastCancer treatment? @Larvol CLIN highlights the innovators who stood out at @SABCSSanAntonio 2024.

Discover more: https://t.co/xWjV8JNFcW

#LARVOL #SABCS24 #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates

[LARVOL @Larvol]

Discover key discussions and reactions on top trials from @SABCSSanAntonio 2024 with @Larvol CLIN.

Learn More: https://t.co/xWjV8JNFcW

#LARVOL #SABCS24 #Oncology #CancerResearch #BreastCancer #CancerData #CancerCare #OncologyUpdates

[Ilana Schlam @IlanaSchlam]

Wrapping up another fantastic #SABCS!

Amazing, practice-changing data were presented.

I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!

#SABCS24 @OncoAlert

[OncoDaily @oncodaily]

📡SOLTI-2103 VALENTINE Trial: Phase II Trial of Neoadjuvant Patritumab Deruxtecan vs. Chemotherapy for High-Risk HR+/HER2- Early Breast Cancer

The SOLTI-2103 VALENTINE trial at SABCS 2024 highlighted the promising potential of HER3-DXd in neoadjuvant treatment for high-risk HR+/HER2- early breast cancer, showing comparable pathological complete response rates to chemotherapy, but further follow-up is needed to assess its impact on event-free survival and quality of life.
@MOliveira_MD @_SOLTI @stolaney1 @GaiaGriguolo @SuyogCancer @puneetsinghmd @JLSandoval

Discover more about the SOLTI VALENTINE trial and its potential in breast cancer treatment:
https://t.co/9U1tOLMPEM

#BreastCancer #OncoDaily #Oncology #SABCS24 #MedEd #MedX #MedNews #Medicine

[José Sandoval @JLSandoval]

CamRelief, early TNBC, NACT +/- periop Camrelizumab (#SABCS24):

- Cape allowed.
- pCR rate improved (12% delta).
- No EFS benefit yet (immature).

Looking similar to GeparDouze. Diff with KN522 a question of anti-PD-1 vs anti-PD-L1, or cape being permitted? Both? Asian patients?

[José Sandoval @JLSandoval]

GeparDouze trial in early TNBC, NACT +/- periop Atezo at #SABCS24:

- No EFS benefit
- Cape allowed from Feb 2020 (why not earlier?)
- No clear EFS differences by pCR status.

Another negative trial for Atezo. How would KN522 results have differed if Cape had been allowed? 🤔

[José Sandoval @JLSandoval]

Anthracyclines in High Genomic Risk N0 HR+/HER2- EBC in TAILORx (#SABCS24):

- RS 31 cutoff predicts 5y DRFI benefit with Anthra
-mainly in postmenopausal (OFS effect?).
- Note: ttt not randomised.

🧠 Vogl NY asks: Could Ki67 offer similar predictive insights?🙃

[José Sandoval @JLSandoval]

ZEST trial: Niraparib in patients with MRD (ctDNA+ during ctDNA surveillance) EBC (TNBC or tBRCA+) (#SABCS24):

- Only 147/1901 patients had ctDNA+, 40 randomised
- 800 to be randomised
- study terminated

Cautionary tale on the challenges of doing MRD-guided RCTs in EBC.

[José Sandoval @JLSandoval]

PATINA trial in HER2+ ER+ MBC, Trast+Pert+ET +/- Palbociclib (#SABCS24):

- PFS benefit: 44 vs 29 months👏
- No clear OS benefit
- Worse toxicity profile.

DB09 data in 6 months and T-DXd likely moving to 1L. the future role of PATINA uncertain. Complex decisions ahead!🤔

[José Sandoval @JLSandoval]

Important study from EBCCTG on obesity & prognosis in EBC (#SABCS24):

- Strong link: Worse outcomes with higher BMI.
- Especially impactful in premenopausal women.
- Independent of LN and ER status.

A stark reminder of the broader consequences of the obesity epidemic. 🌍

[José Sandoval @JLSandoval]

COMET trial, active monitoring vs surgery (+/-RT) in low risk DCIS at #SABCS24 :

- 2y IBC rate non-inferior (dif: 1.7%)
- most got Adj ET
- 31% women didn't adhere to randomisation, favouring AM

But is QoL better than surgery + RT w/o ET?

https://t.co/PIY4qxIHfL